ArticleFrontiers in cardiovascular medicine2025
Impact of anticoagulation management following endovascular therapy on prognosis of patients with atrial fibrillation and acute ischemic stroke.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the impact of early oral anticoagulant (OAC) initiation at hospital discharge on functional and safety outcomes in atrial fibrillation (AF)-related acute ischemic stroke (AIS) patients undergoing endovascular therapy (EVT). Methods: AF patients undergoing EVT of symptom onset in AIS were included in this study. Patients were grouped by postoperative anticoagulation status. The patients were regularly followed up 90 days and 1 year after discharge. The primary outcome measure for assessing prognosis is the modified Rankin Scale (mRS) score. The secondary evaluation indicators were the occurrence of recurrent ischemic stroke/systemic embolism (IS/SE) outcomes, safety outcomes, and all-cause mortality outcomes within 1 year. The differences in prognostic indicators between the two groups were compared by combining PSM. Results: Among the 296 eligible patients, 113 (38.18%) received anticoagulation at discharge, while 183 (61.82%) did not. Before PSM, the anticoagulation cohort exhibited markedly elevated rates of favorable functional outcomes at 90 days post-discharge (mRS 0-2: 60.18% vs. 25.14%, Conclusion: In patients with AF complicated by stroke who underwent EVT and were at no high risk for severe bleeding, OAC therapy is associated with improved functional and mortality outcomes compared with those not receiving OAC. The benefit remained statistically significant following PSM to adjust for intergroup disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.